Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

NCT00900562 2021-10-28

Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy

PharmaMar

Phase 2 Terminated
19 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Endometrial Neoplasms

NCT00359294 2021-07-28

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

PharmaMar

Phase 1 Terminated
12 enrolled 13 charts
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡